Association between survivin gene promoter-31G/C and-644C/T polymorphisms and non-small cell lung cancer

被引:16
作者
Aynaci, E. [1 ]
Coskunpinar, E. [2 ]
Eren, A. [2 ]
Kum, O. [1 ]
Oltulu, Y. M. [2 ]
Akkaya, N. [2 ]
Turna, A. [3 ]
Yaylim, I. [2 ]
Yildiz, P. [1 ]
机构
[1] Yedikule Chest Dis & Thorac Surg Training & Res H, Istanbul, Turkey
[2] Istanbul Univ, Inst Expt Med, Dept Mol Med, Istanbul, Turkey
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Thorac Surg, Istanbul, Turkey
关键词
Non-small cell lung cancer; Survivin; Gene polymorphism; Genetics; Biomarker; THERAPEUTIC TARGET; MESSENGER-RNA; RISK; EXPRESSION; CARCINOMA; INHIBITOR;
D O I
10.4238/2013.February.28.9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lung cancer is the most common cancer worldwide. Survivin is one of the first reported inhibitors of apoptosis proteins, which is an important family of proteins that regulate apoptosis. The survivin gene is located on human chromosome 17q25, which is composed of 142 amino acids. A common polymorphism of the survivin gene promoter -31G/C has been shown to influence cancer risk. This genetic variant has been associated with overexpression of survivin at both protein and mRNA levels in cancer cells. We examined promoter (-31G/C) genotype frequency in a patient group (N = 146), 77.4% GG, 18.5% GC, 4.1% CC, and in a control group (N = 98), 57.1% GG, 34.7% GC, 8.2% CC. These distributions were significantly different. Promoter (-644C/T) genotype frequency in the patient group was 40.4% TT, 48.6% TC, 11% CC, and in the control group it was 55.1% TT, 40.8% TC, 4.1% CC; these distributions were also significantly different. Individuals carrying the survivin 31 GC genotype and those carrying the survivin 644 CC genotype had a significantly decreased risk of having non-small cell lung cancer.
引用
收藏
页码:3975 / 3982
页数:8
相关论文
共 22 条
  • [1] Adida C, 1998, AM J PATHOL, V152, P43
  • [2] Validating survivin as a cancer therapeutic target
    Altieri, DC
    [J]. NATURE REVIEWS CANCER, 2003, 3 (01) : 46 - 54
  • [3] Chiou SK, 2003, MED SCI MONITOR, V9, pPI25
  • [4] Prognostic Significance of Survivin Polymorphisms on Non-small Cell Lung Cancer Survival
    Dai, Juncheng
    Jin, Guangfu
    Dong, Jing
    Chen, Yijiang
    Xu, Lin
    Hu, Zhibin
    Shen, Hongbing
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (11) : 1748 - 1754
  • [5] X-linked IAP is a direct inhibitor of cell-death proteases
    Deveraux, QL
    Takahashi, R
    Salvesen, GS
    Reed, JC
    [J]. NATURE, 1997, 388 (6639) : 300 - 304
  • [6] Drabek Jiri, 2002, Biomedical Papers (Olomouc), V146, P37, DOI 10.5507/bp.2002.007
  • [7] Survivin-31G/C promoter polymorphism and sporadic colorectal cancer
    Gazouli, Maria
    Tzanakis, Nikolaos
    Rallis, George
    Theodoropoulos, George
    Papaconstantinou, Ioannis
    Kostakis, Alkiviadis
    Anagnou, Nicholas P.
    Nikiteas, Nikolaos
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (02) : 145 - 150
  • [8] Polymorphisms in the survivin gene and the risk of lung cancer
    Jang, Jin Sung
    Kim, Kyung Mee
    Kang, Kyung Hee
    Choi, Jin Eun
    Lee, Won Kee
    Kim, Chang Ho
    Kang, Young Mo
    Kam, Sin
    Kim, In-San
    Jun, Jae Eun
    Jung, Tae Hoon
    Park, Jae Yong
    [J]. LUNG CANCER, 2008, 60 (01) : 31 - 39
  • [9] Essential role for survivin in early brain development
    Jiang, YY
    de Bruin, A
    Caldas, H
    Fangusaro, J
    Hayes, J
    Conway, EM
    Robinson, ML
    Altura, RA
    [J]. JOURNAL OF NEUROSCIENCE, 2005, 25 (30) : 6962 - 6970
  • [10] Survivin acts as an antiapoptotic factor during the development of mouse preimplantation embryos
    Kawamura, K
    Sato, N
    Fukuda, J
    Kodama, H
    Kumagai, J
    Tanikawa, H
    Shimizu, Y
    Tanaka, T
    [J]. DEVELOPMENTAL BIOLOGY, 2003, 256 (02) : 331 - 341